These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

104 related articles for article (PubMed ID: 35590147)

  • 41. Circulating Tumor DNA in Stage III Colorectal Cancer, beyond Minimal Residual Disease Detection, toward Assessment of Adjuvant Therapy Efficacy and Clinical Behavior of Recurrences.
    Henriksen TV; Tarazona N; Frydendahl A; Reinert T; Gimeno-Valiente F; Carbonell-Asins JA; Sharma S; Renner D; Hafez D; Roda D; Huerta M; Roselló S; Madsen AH; Løve US; Andersen PV; Thorlacius-Ussing O; Iversen LH; Gotschalck KA; Sethi H; Aleshin A; Cervantes A; Andersen CL
    Clin Cancer Res; 2022 Feb; 28(3):507-517. PubMed ID: 34625408
    [TBL] [Abstract][Full Text] [Related]  

  • 42. Serial Circulating Tumor DNA Analysis with a Tumor-Naïve Next-Generation Sequencing Panel Detects Minimal Residual Disease and Predicts Outcome in Ovarian Cancer.
    Heo J; Kim YN; Shin S; Lee K; Lee JH; Lee YJ; Choi Z; Park J; Min S; Kim SW; Choi JR; Kim S; Lee ST; Lee JY
    Cancer Res; 2024 Feb; 84(3):468-478. PubMed ID: 38038965
    [TBL] [Abstract][Full Text] [Related]  

  • 43. Circulating tumor DNA (ctDNA) to evaluate minimal residual disease (MRD), treatment response, and posttreatment prognosis in pancreatic adenocarcinoma.
    Ueberroth BE; Jones JC; Bekaii-Saab TS
    Pancreatology; 2022 Sep; 22(6):741-748. PubMed ID: 35725696
    [TBL] [Abstract][Full Text] [Related]  

  • 44. Genotyping of circulating cell-free DNA enables noninvasive tumor detection in myxoid liposarcomas.
    Braig D; Becherer C; Bickert C; Braig M; Claus R; Eisenhardt AE; Heinz J; Scholber J; Herget GW; Bronsert P; Fricke A; Follo M; Stark GB; Bannasch H; Eisenhardt SU
    Int J Cancer; 2019 Aug; 145(4):1148-1161. PubMed ID: 30779112
    [TBL] [Abstract][Full Text] [Related]  

  • 45. Relationship between post-surgery detection of methylated circulating tumor DNA with risk of residual disease and recurrence-free survival.
    Murray DH; Symonds EL; Young GP; Byrne S; Rabbitt P; Roy A; Cornthwaite K; Karapetis CS; Pedersen SK
    J Cancer Res Clin Oncol; 2018 Sep; 144(9):1741-1750. PubMed ID: 29992492
    [TBL] [Abstract][Full Text] [Related]  

  • 46. Detection of circulating tumour DNA after neoadjuvant chemoradiotherapy in patients with locally advanced oesophageal cancer.
    Eyck BM; Jansen MP; Noordman BJ; Atmodimedjo PN; van der Wilk BJ; Martens JW; Helmijr JA; Beaufort CM; Mostert B; Doukas M; Wijnhoven BP; Lagarde SM; van Lanschot JJB; Dinjens WN
    J Pathol; 2023 Jan; 259(1):35-45. PubMed ID: 36196486
    [TBL] [Abstract][Full Text] [Related]  

  • 47. Liquid biopsy in lymphoma: Molecular methods and clinical applications.
    Cirillo M; Craig AFM; Borchmann S; Kurtz DM
    Cancer Treat Rev; 2020 Dec; 91():102106. PubMed ID: 33049623
    [TBL] [Abstract][Full Text] [Related]  

  • 48. Dynamic Treatment Stratification Using ctDNA.
    Vidal J; Taus A; Montagut C
    Recent Results Cancer Res; 2020; 215():263-273. PubMed ID: 31605234
    [TBL] [Abstract][Full Text] [Related]  

  • 49. Early Detection of Molecular Residual Disease and Risk Stratification for Stage I to III Colorectal Cancer via Circulating Tumor DNA Methylation.
    Mo S; Ye L; Wang D; Han L; Zhou S; Wang H; Dai W; Wang Y; Luo W; Wang R; Xu Y; Cai S; Liu R; Wang Z; Cai G
    JAMA Oncol; 2023 Jun; 9(6):770-778. PubMed ID: 37079312
    [TBL] [Abstract][Full Text] [Related]  

  • 50. Dynamic recurrence risk and adjuvant chemotherapy benefit prediction by ctDNA in resected NSCLC.
    Qiu B; Guo W; Zhang F; Lv F; Ji Y; Peng Y; Chen X; Bao H; Xu Y; Shao Y; Tan F; Xue Q; Gao S; He J
    Nat Commun; 2021 Nov; 12(1):6770. PubMed ID: 34799585
    [TBL] [Abstract][Full Text] [Related]  

  • 51. Early stage NSCLC - challenges to implementing ctDNA-based screening and MRD detection.
    Abbosh C; Birkbak NJ; Swanton C
    Nat Rev Clin Oncol; 2018 Sep; 15(9):577-586. PubMed ID: 29968853
    [TBL] [Abstract][Full Text] [Related]  

  • 52. Circulating Tumor DNA Minimal Residual Disease Detection of Non-Small-Cell Lung Cancer Treated With Curative Intent.
    Pellini B; Chaudhuri AA
    J Clin Oncol; 2022 Feb; 40(6):567-575. PubMed ID: 34985936
    [TBL] [Abstract][Full Text] [Related]  

  • 53. Circulating Tumor DNA and Minimal Residual Disease (MRD) in Solid Tumors: Current Horizons and Future Perspectives.
    Peng Y; Mei W; Ma K; Zeng C
    Front Oncol; 2021; 11():763790. PubMed ID: 34868984
    [TBL] [Abstract][Full Text] [Related]  

  • 54. Comprehensive Genomic Profiling (CGP)-Informed Personalized Molecular Residual Disease (MRD) Detection: An Exploratory Analysis from the PREDATOR Study of Metastatic Colorectal Cancer (mCRC) Patients Undergoing Surgical Resection.
    Lonardi S; Nimeiri H; Xu C; Zollinger DR; Madison RW; Fine AD; Gjoerup O; Rasola C; Angerilli V; Sharma S; Wu HT; Palsuledesai CC; Malhotra M; Aleshin A; Loupakis F; Renkonen E; Hegde P; Fassan M
    Int J Mol Sci; 2022 Sep; 23(19):. PubMed ID: 36232827
    [TBL] [Abstract][Full Text] [Related]  

  • 55. Circulating tumor DNA-minimal residual disease: An up-and-coming nova in resectable non-small-cell lung cancer.
    Li FQ; Cui JW
    Crit Rev Oncol Hematol; 2022 Nov; 179():103800. PubMed ID: 36031171
    [TBL] [Abstract][Full Text] [Related]  

  • 56. Circulating Tumor DNA in the Management of Early-Stage Breast Cancer.
    Vlataki K; Antonouli S; Kalyvioti C; Lampri E; Kamina S; Mauri D; Harissis HV; Magklara A
    Cells; 2023 Jun; 12(12):. PubMed ID: 37371043
    [TBL] [Abstract][Full Text] [Related]  

  • 57. Minimal Residual Disease Detection using a Plasma-only Circulating Tumor DNA Assay in Patients with Colorectal Cancer.
    Parikh AR; Van Seventer EE; Siravegna G; Hartwig AV; Jaimovich A; He Y; Kanter K; Fish MG; Fosbenner KD; Miao B; Phillips S; Carmichael JH; Sharma N; Jarnagin J; Baiev I; Shah YS; Fetter IJ; Shahzade HA; Allen JN; Blaszkowsky LS; Clark JW; Dubois JS; Franses JW; Giantonio BJ; Goyal L; Klempner SJ; Nipp RD; Roeland EJ; Ryan DP; Weekes CD; Wo JY; Hong TS; Bordeianou L; Ferrone CR; Qadan M; Kunitake H; Berger D; Ricciardi R; Cusack JC; Raymond VM; Talasaz A; Boland GM; Corcoran RB
    Clin Cancer Res; 2021 Oct; 27(20):5586-5594. PubMed ID: 33926918
    [TBL] [Abstract][Full Text] [Related]  

  • 58. Circulating Tumor DNA as a Marker of Minimal Residual Disease After Radical Resection of Colorectal Liver Metastases.
    Marmorino F; Prisciandaro M; Giordano M; Ortolan E; Crucitta S; Manca P; Antoniotti C; Valenti MM; Danesi R; Conca V; Mazzoli G; Boccaccino A; Carullo M; Martinetti A; Sottotetti E; Masi G; Sposito C; Zaffaroni N; Milione M; Fontanini G; Del Re M; Pietrantonio F; Cremolini C
    JCO Precis Oncol; 2022 Nov; 6():e2200244. PubMed ID: 36356286
    [TBL] [Abstract][Full Text] [Related]  

  • 59. Circulating tumor DNA in early-stage breast cancer: new directions and potential clinical applications.
    Croessmann S; Park BH
    Clin Adv Hematol Oncol; 2021 Mar; 19(3):155-161. PubMed ID: 33739964
    [TBL] [Abstract][Full Text] [Related]  

  • 60. The potential role of circulating tumor DNA (ctDNA) in the further investigation of colorectal cancer patients with nonspecific findings on standard investigations.
    Wong R; Tie J; Lee M; Cohen J; Wang Y; Li L; Ma S; Christie M; Kosmider S; Tomasetti C; Papadopoulos N; Kinzler KW; Vogelstein B; Gibbs P
    Int J Cancer; 2019 Jul; 145(2):540-547. PubMed ID: 30628066
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 6.